This dataset is a random generated dataset to reproduce the numbers needed to generate the flowchart of the SAFO study. SAFO is an open-label, multicenter, phase III–IV superiority randomized clinical trial to assess whether cloxacillin plus fosfomycin administered for the initial 7-days of therapy achieves better treatment success than cloxacillin alone in hospitalized patients with MSSA bacteremia.
Usage
data(safo)Format
A data frame with 925 rows and 21 columns
- id:
Identifier of each patient. This information does not match the real data.
- inclusion_crit:
The patient not met the inclusion criteria?
- exclusion_crit:
The patient met the exclusion criteria?
- chronic_heart_failure:
Exc1: Chronic heart failure?
- expected_death_24h:
Exc2: Clinical status with expected death in <24h?
- polymicrobial_bacteremia:
Exc3: Polymicrobial bacteremia?
- conditions_affect_adhrence:
Exc4: Conditions expected to affect adhrence to the protocol?
- susp_prosthetic_valve_endocard:
Exc5: Suspicion of prosthetic valve endocarditis?
- severe_liver_cirrhosis:
Exc6: Severe liver cirrhosis?
- acute_sars_cov2:
Exc7: Acute SARS-CoV-2 infection?
- blactam_fosfomycin_hypersens:
Exc8: Beta-lactam or fosfomycin hypersensitivity?
- other_clinical_trial:
Exc9: Participation in another clinical trial?
- pregnancy_or_breastfeeding:
Exc10: Pregnancy or breastfeeding?
- previous_participation:
Exc11: Previous participation in the SAFO trial?
- myasthenia_gravis:
Exc12: Myasthenia gravis?
- decline_part:
The patient declined to participate?
- group:
Randomized treatment received: cloxacilin alone / cloxacilin plus fosfomycin
- itt:
The patient belongs to the intention to treat (ITT) group?
- reason_itt:
Reason for exclusion from the ITT group.
- pp:
The patient belongs to the per protocol (PP) group?
- reason_pp:
Reason for exclusion from the PP group.